Emma Searle

Has grant

The University of Manchester

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Cancer Biology Cancer Biology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Improving Outcomes in Elderly Patients with Myeloma through Targeting of the Tumour Microenvironment

Open Date: 2019-02-01

Close Date: 2020-07-31

Grant: Close

Targeting the Akt pathway with AZD5363 in combination with radiotherapy to improve tumour control in head and neck cancer

Open Date: 2017-09-01

Close Date:

Articles (12)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Collaborators (5)

Mhairi Copland

Professor of Translational Haematology

University of Glasgow

UNITED KINGDOM

View details

Nizar J. Bahlis

University of Calgary

CANADA

View details

Joaquin Martinez-Lopez

SPAIN

View details

Daniel Wiseman

The University of Manchester

UNITED KINGDOM

View details

Delfim Duarte

Invited Assistant Professor

PORTUGAL

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Emma Searle

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (12)

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

An open-label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced hematological malignancies

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies

Polb 001, an Oral Broad-Spectrum Anti-Inflammatory with the Potential to Prevent Cytokine Release Syndrome ( CRS)

Targeting hypoxia in solid and haematological malignancies

The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy

Collaborators (5)

Mhairi Copland

Nizar J. Bahlis

Joaquin Martinez-Lopez

Daniel Wiseman

Delfim Duarte

Make your next move.